Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jinqi Qingshu Granules is a Traditional Chinese Medicine (TCM) hospital-made preparation developed by the Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, affiliated with the Shanghai University of Traditional Chinese Medicine. The formula was designed for the management of mild COVID-19 symptoms, particularly during the Omicron variant outbreaks in Shanghai. As a proprietary Chinese medicine, it is intended to clear heat, detoxify, and support the body's immune response. It has been studied in real-world clinical practice through observational registry trials to evaluate its effectiveness in promoting symptom recovery and viral clearance in adult patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on jinqi qingshu granules.